Exact Mass: 375.2256908
Exact Mass Matches: 375.2256908
Found 429 metabolites which its exact mass value is equals to given mass value 375.2256908,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Icaceine
A diterpene alkaloid that is 6,18:14,16-diepoxypimar-7-en-18-one substituted by a hydroxy group at position 3 and a dimethyl amino group at position 15. It is isolated from Icacina guessfeldtii.
Cyphenothrin
C24H25NO3 (375.18343400000003)
D010575 - Pesticides > D007306 - Insecticides > D011722 - Pyrethrins Same as: D01511
3,5-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,5-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,5-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,5-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,5-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,10-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,10-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,10-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,10-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,10-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,9-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,9-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,9-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,9-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,9-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,6-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,6-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,6-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,6-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,6-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,8-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,8-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,8-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,8-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,8-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,7-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,7-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,7-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,7-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,7-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,4-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,4-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,4-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,11-Dihydroxydodecanoylcarnitine
C19H37NO6 (375.26207420000003)
3,11-Dihydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3,11-Dihydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,11-Dihydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,11-Dihydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(E)-1-[(2R)-2-(2-Hydroxyethyl)piperidin-1-yl]-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-en-1-one
Pipamperone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Pipamperone (Floropipamide; McN-JR 3345; R 3345) is a high-affinity antagonist of 5-HT2A receptor (pKi=8.2) and D4 receptor (pKi=8.0) and a low-affinity antagonist of D2 receptor (pKi=6.7)[1].
Phe-Pro-Ile
C20H29N3O4 (375.21579540000005)
Tuberstemonine
Tuberostemonine is an alkaloid. It has a role as a metabolite. Tuberostemonine is a natural product found in Stemona tuberosa, Stemona sessilifolia, and other organisms with data available. A natural product found in Stemona phyllantha and Stemona tuberosa. relative retention time with respect to 9-anthracene Carboxylic Acid is 0.534 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.531 Tuberostemonine, an alkaloid, is an antimalarial agent that targets Plasmodium falciparum ferredoxin-NADP+ reductases (pfFNR)[1]. Tuberostemonine, an alkaloid, is an antimalarial agent that targets Plasmodium falciparum ferredoxin-NADP+ reductases (pfFNR)[1].
Pipamperone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent CONFIDENCE standard compound; INTERNAL_ID 2514 Pipamperone (Floropipamide; McN-JR 3345; R 3345) is a high-affinity antagonist of 5-HT2A receptor (pKi=8.2) and D4 receptor (pKi=8.0) and a low-affinity antagonist of D2 receptor (pKi=6.7)[1].
pyrrole-2-carboxylic acid 9-hydroxymethyl-7-(6-oxo-piperidin-2-yl)-octahydro-quinolizin-2-yl ester
C20H29N3O4 (375.21579540000005)
9-O-(threo-2-hydroxy-2-methyl-3-phenylacetoxy-butyryl)-(-)-trachelanthamidine|minalobine R
C21H29NO5 (375.20456240000004)
9-(1-hydroxyhexyl)-3-(2-hydroxypropyl)-6a-methyl-9,9a-dihydrofuro[2,3-h]isoquinoline-6,8(2h,6ah)-dione
C21H29NO5 (375.20456240000004)
erythro-1-[1-oxo-9(3,4-methylenedioxyphenyl)-8,9-dihydroxy-2E-nonenyl]-piperidine|threo-1-[1-oxo-9(3,4-methylenedioxyphenyl)-8,9-dihydroxy-2E-nonenyl]-piperidine
C21H29NO5 (375.20456240000004)
2-heptadec-11-enamidoethanesulfonic acid
C19H37NO4S (375.24431620000007)
20-ethyl-8-hydroxy-1alpha-methoxy-4-methyl-heteratisan-14-one|6-deoxy-heteratisine|Hetereophyllisin|heterophyllisine
2alpha-hydroxy-comosivine|2alpha-Hydroxycomosivine
C21H29NO5 (375.20456240000004)
Neotuberostemonine
Neotuberostemonine is an alkaloid. It has a role as a metabolite. Neotuberostemonine is a natural product found in Stemona tuberosa, Stemona phyllantha, and other organisms with data available. A natural product found in Stemona tuberosa and Stemona phyllantha. Neotuberostemonine, one of the main antitussive alkaloids in the root of Stemona tuberosa Lour, attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages[1]. Neotuberostemonine, one of the main antitussive alkaloids in the root of Stemona tuberosa Lour, attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages[1].
Napelline N-oxide
Origin: Plant; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid
R-4-benzyl-3-((R)-3-hydroxy-2,2-dimethyloctanoyl)-5,5-dimethyloxazolidin-2-one
S-4-benzyl-3-((S)-3-hydroxy-2,2-dimethyloctanoyl) -5,5-dimethyloxazolidin-2-one
Ala Ala Lys Ser
Ala Ala Ser Lys
Ala Gly Lys Thr
Ala Gly Thr Lys
Ala Lys Ala Ser
Ala Lys Gly Thr
Ala Lys Ser Ala
Ala Lys Thr Gly
Ala Ser Ala Lys
Ala Ser Lys Ala
Ala Thr Gly Lys
Ala Thr Lys Gly
Gly Ala Lys Thr
Gly Ala Thr Lys
Gly Gly Arg Ser
Gly Gly Ser Arg
Gly Lys Ala Thr
Gly Lys Thr Ala
Gly Arg Gly Ser
Gly Arg Ser Gly
Gly Ser Gly Arg
Gly Ser Arg Gly
Gly Thr Ala Lys
Gly Thr Lys Ala
Lys Ala Ala Ser
Lys Ala Gly Thr
Lys Ala Ser Ala
Lys Ala Thr Gly
Lys Gly Ala Thr
Lys Gly Thr Ala
Lys Ser Ala Ala
Lys Thr Ala Gly
Lys Thr Gly Ala
Arg Gly Gly Ser
Arg Gly Ser Gly
Arg Ser Gly Gly
Ser Ala Ala Lys
Ser Ala Lys Ala
Ser Gly Gly Arg
Ser Gly Arg Gly
Ser Lys Ala Ala
Ser Arg Gly Gly
Thr Ala Gly Lys
Thr Ala Lys Gly
Thr Gly Ala Lys
Thr Gly Lys Ala
Thr Lys Ala Gly
Thr Lys Gly Ala
S-4-benzyl-3-((S)-3-hydroxy-2,2-dimethyloctanoyl)-5,5-dimethyloxazolidin-2-one
R-4-benzyl-3-((R)-3-hydroxy-2,2-dimethyloctanoyl)-5,5-dimethyloxazolidin-2-one
N1,N1-dimethyl-4-[[4-(dimethylamino)phenyl](4-nitrophenyl)methyl]aniline
JWH 018 N-pentanoic acid metabolite-d4
C24H17D4NO3 (375.17724431199997)
N-(15-methyl-2,3,4-trihydroxy-hexadecanoyl)-glycine
C19H37NO6 (375.26207420000003)
Asc C11 EA
C19H37NO6 (375.26207420000003)
sodium (Z)-N-methyl-N-(1-oxo-9-octadecenyl)aminoacetate
propoxyphene hydrochloride
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
4,4-bis(dimethylamino)-4-(methylamino)trityl alcohol
2-N,N-DIBENZYL SERINE BENZYL ESTER
C24H25NO3 (375.18343400000003)
3-[2-(1-benzylpiperidin-4-yl)ethyl]-2,5-dihydropyrrolo[3,2-f][1,2]benzoxazol-6-one
3-Pyridinemethanol, 5-butyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aR)-
butyl prop-2-enoate,prop-2-enamide,prop-2-enoic acid,styrene
C21H29NO5 (375.20456240000004)
3-Pyridinemethanol, 5-butyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aR,4R)- (9CI)
3-Pyridinemethanol, 5-butyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aR,4S)- (9CI)
1-METHYL-4-(4-FLUOROPHENYL)-PIPERIDINE-3-CARBOXYLIC ACID MENTHYL ESTER
sodium N-methyl-N-(1-oxo-9-octadecenyl)aminoacetate
2-[[2-(4-HYDROXYPHENYL)ETHYL]AMINO]-1-[4-(PHENYLMETHOXY)PHENYL]-1-PROPANONE
C24H25NO3 (375.18343400000003)
4-methyl-N-(4-methylphenyl)-N-[4-(2-phenylethenyl)phenyl]aniline
6-Benzyl 2-tert-butyl 2,6,9-triazaspiro[4.5]decane-2,6-dicarboxylate
C20H29N3O4 (375.21579540000005)
TERT-BUTYL 4-(1-(BENZYLOXYCARBONYL)AZETIDIN-3-YL)PIPERAZINE-1-CARBOXYLATE
C20H29N3O4 (375.21579540000005)
3-Pyridinemethanol, 5-butyl-4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-, (aS)-
[5-[3-(1,3-dioxolan-2-yl)propyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
C19H26BNO6 (375.18530860000004)
Benzylmorphine
C24H25NO3 (375.18343400000003)
Difeterol
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
9-Benzyl 2-Tert-Butyl 2,6,9-Triazaspiro[4.5]Decane-2,9-Dicarboxylate
C20H29N3O4 (375.21579540000005)
p-cyanophenyl trans-p-(4-pentylcyclohexyl)benzoate
4-((4-(DIETHYLAMINO)-2-METHYLPHENYL)IMINO)-N-METHYL-1-OXO-1,4-DIHYDRONAPHTHALENE-2-CARBOXAMIDE
4-((4-(ETHYL(ISOPROPYL)AMINO)PHENYL)IMINO)-N-METHYL-1-OXO-1,4-DIHYDRONAPHTHALENE-2-CARBOXAMIDE
Tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate
1,4,7-Trihydroxy-3-(2-hydroxyethyl)-3,4,5-heptanetricarboxylic acid triammonium salt
cis-(+/-)-2-[(N-Benzyl-N-methyl)aminomethyl]-1-(3-methoxyphenyl)cyclohexanol, Hydrochloride
4-Cyano-3,5-difluorophenyl 4-ethyl-[1,1-bi(cyclohexane)]-4-carboxylate
C22H27F2NO2 (375.20097460000005)
tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carboxylate
Undecyl2-acetamido-2-deoxy-b-D-glucopyranoside
C19H37NO6 (375.26207420000003)
6-(4-Methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(Z)-2- phenylvinyl]-4-pyrimidinamine
benzyl 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]azetidin-1-yl]pyrrolidine-1-carboxylate
C20H29N3O4 (375.21579540000005)
Pentazocine lactate
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists D002491 - Central Nervous System Agents > D000700 - Analgesics
2-Piperidineethanol, 1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-, (E)-
3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
11-[2-(4-Morpholinyl)ethylamino]-7,8,9,10-tetrahydrobenzimidazolo[1,2-b]isoquinoline-6-carbonitrile
4-[(4-tert-butylphenyl)-oxomethyl]-N-[2-(2-pyridinyl)ethyl]-1H-pyrrole-2-carboxamide
(S)-cyano(3-phenoxyphenyl)methyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate
C24H25NO3 (375.18343400000003)
11-((3-morpholinopropyl)amino)-2,3-dihydro-1H-benzo[4,5]imidazo[1,2-a]cyclopenta[d]pyridine-4-carbonitrile
(2Z)-2-cyano-N-(4-ethoxyphenyl)-3-[3-methyl-4-(pyrrolidin-1-yl)phenyl]prop-2-enamide
1-(3-(1-(2-Morpholinoethyl)-1H-pyrazol-3-yl)biphenyl-3-yl)ethanone
6-Ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-YL]pyrimidine-2,4-diamine
(2r,6s)-6-{[methyl(3,4,5-Trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-Hexahydroquinazoline-2,4-Diamine
(4Z,7S,8E,10Z,12E,14E,16R,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoate
N-[2-(4-{[5-(aminomethyl)furan-3-yl]methoxy}phenyl)ethyl]-L-glutamine
(4S,5E,7Z,10Z,13Z,15E,17R,19Z)-4-hydroperoxy17-hydroxydocosa-5,7,10,13,15,19-hexaenoate
(4S,5E,7Z,10Z,13Z,15E,17S,19Z)-4-hydroperoxy-17-hydroxydocosa-5,7,10,13,15,19-hexaenoate
(4Z,7S,8E,10Z,13E,15Z,17S,19Z)7-hydroperoxy-17-hydroxydocosa-4,8,10,13,15,19-hexaenoate
4S,11R,17S-trihydroxy-5Z,7E,9E,13Z,15E,19Z-docosahexaenoate
tuberostemonine N
A natural product found in Stemona tuberosa and Stemona phyllantha.
[4-(2-Methoxyphenyl)-1-piperidinyl]-(5-methyl-1-phenyl-4-pyrazolyl)methanone
17-Dimethylaminolobohedleolide
A cembrane diterpenoid isolated from Lobophytum and shown to have anti-HIV-1 activity.
(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxybutanoyl]amino]hexanoic acid
N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N(2),N(2)-dimethylglycinamide
7-ethyl-1-[(phenylmethyl)amino]-3-(1-piperidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile
(9E)-12-(phosphonooxy)octadecenoate(3-)
C18H32O6P-3 (375.19364020000006)
(9Z)-12-(phosphonooxy)octadecenoate(3-)
C18H32O6P-3 (375.19364020000006)
1-(3,5-Dimethyl-1-pyrazolyl)-3-[2-(4-methoxyphenyl)-1-indolyl]-2-propanol
7,8-dimethyl-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4-phenyl-3H-1,5-benzodiazepin-2-one
1-[1-[(4-Hydroxy-1-piperidinyl)-oxomethyl]cyclohexyl]-3-(2-methoxyphenyl)urea
C20H29N3O4 (375.21579540000005)
2-[[4-(3,5-Ditert-butylpyrazol-1-yl)phenyl]iminomethyl]phenol
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-cyclohexyl-3-methyl-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide
(1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate hydrochloride
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide
C20H29N3O4 (375.21579540000005)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[[(2S,3R,4S)-3-[4-(3-cyanophenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]cyclobutanecarboxamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclopropanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide
C20H29N3O4 (375.21579540000005)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
10(R),17(S),20-trihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate
(3R)-13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxytridecanoate
(3R,12R)-12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxytridecanoate
Dibutyl 1-(N-trifluoroacetylamino)pentylphosphonate
C15H29F3NO4P (375.1786200000001)
Dibutyl 3-methyl-1-(N-trifluoroacetylamino)butylphosphonate
C15H29F3NO4P (375.1786200000001)
4-[2,3-Di(butanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate
4-(3-Acetyloxy-2-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Pentanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
2-(2-Trimethylsilyloxyethoxy)-N-(2-(ethylaminoethyl)-4-quinolinecarboxamide
C19H29N3O3Si (375.19780840000004)
(2S)-2-[1-Oxo-4-(tetrahydro-2H-pyran-2-yloxy)butyl]pyrrolidine-1-carboxylic acid benzyl ester
C21H29NO5 (375.20456240000004)
(1R,4S,5R,7R,8S,13R,16S,17S)-11-ethyl-13-methyl-6-methylidene-11-oxido-11-azoniahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol
resolvin D2(1-)
A polyunsaturated fatty acid anion that is the conjugate base of resolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4-{4-[2-(gamma-L-glutamylamino)ethyl]phenoxymethyl}furan-2-yl)methanamine
A L-glutamine derivative obtained by formal condensation of the side-chain carboxy group of L-glutamine with one of the amino groups of 2-(4-{[5-(aminomethyl)furan-3-yl]methoxy}phenyl)ethan-1-amine.
22-hydroxyprotectin D1(1-)
A docosanoid anion that is the conjugate base of 22-hydroxyprotectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
LML134
LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders[1].
(1s,3s,9r,10r,11r,14r,15r,16s)-10-ethyl-14-methyl-3-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
(1r,2s,3r,4r,5s,7r,8r,12r,13s,21r)-4,12-dimethyl-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosane-3,4-diol
(1r,2s,3r,4s,5s,7r,8r,12r,13s,21r)-4,12-dimethyl-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosane-3,4-diol
(1s,3r,9s,10s,11s,14r,15s,16s)-10-ethyl-14-methyl-3-[(2r,4r)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
12-ethyl-9-hydroxy-17-methoxy-14-methyl-5-oxa-12-azahexacyclo[8.7.2.1²,⁶.0¹,¹¹.0³,⁹.0¹⁴,¹⁸]icosan-4-one
1,6,11-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,6h,6ah,7h,10h,11h,12h-cyclonona[d]isoindol-13-one
(2r,7r,9r,9as)-7-[(2r)-6-hydroxy-2,3,4,5-tetrahydropyridin-2-yl]-9-(hydroxymethyl)-octahydro-1h-quinolizin-2-yl 1h-pyrrole-2-carboxylate
C20H29N3O4 (375.21579540000005)
(1r,7r,10r,11s,15s,18s,21r,22r,23r)-21,23-dihydroxy-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricosan-4-one
8-methyl-6-[(2-methylpropanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
C21H29NO5 (375.20456240000004)
(1r,4s,5r,7r,8s,13r,16s)-11-ethyl-4,7,16-trihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-11-ium-11-olate
(6ar,9r,9ar)-9-[(1s)-1-hydroxyhexyl]-3-[(2s)-2-hydroxypropyl]-6a-methyl-2h,9h,9ah-furo[2,3-h]isoquinoline-6,8-dione
C21H29NO5 (375.20456240000004)
(1s,2r,4r,5r,7r,8s,9r,11r,13s,16s,17r)-11-ethyl-4,7,16-trihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-11-ium-11-olate
(1s,2r,4r,5s,7r,8r,12r,13r,18r,20s,21r)-4,12-dimethyl-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosane-4,20-diol
(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s,3s)-2-hydroxy-2-methyl-3-[(2-phenylacetyl)oxy]butanoate
C21H29NO5 (375.20456240000004)
5-(4-cyclopropyl-2-methylbuta-1,3-dien-1-yl)-7-hydroxy-7-methyl-hexahydro-1ah-oxireno[2,3-g]indolizin-6-yl 3-methylbutanoate
(1r,11s,21r)-21,23-dihydroxy-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricosan-4-one
(2r,4ar,7r,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl (hydroxycarbamoyl)formate
(1as,5r,6r,7r,7as,7br)-5-[(1e,3e)-4-cyclopropyl-2-methylbuta-1,3-dien-1-yl]-7-hydroxy-7-methyl-hexahydro-1ah-oxireno[2,3-g]indolizin-6-yl 3-methylbutanoate
3-[15-hydroxy-12-(hydroxymethyl)-16-methyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-3-yl]propanoic acid
(1s,2r,4r,5r,7r,8r,9r,10r,13r,14r,16s,17r)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,14,16-tetrol
(1r,3s,9r,10r,11r,14s,15s,16r)-10-ethyl-14-methyl-3-[(2r,4s)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
3-[(2s,5s,8s)-5-benzyl-3,6,9-trihydroxy-8-isopropyl-5,8-dihydro-2h-1,4,7-triazonin-2-yl]propanoic acid
(1s,12s,14s)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17)-trien-14-yl (3s)-3-hydroxybutanoate
C21H29NO5 (375.20456240000004)
10-methoxy-3-methyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole-8-carbaldehyde
C24H25NO3 (375.18343400000003)
(1s,2r,3s,6r,9s,10s,11r,14r,17s,18r)-12-ethyl-9-hydroxy-17-methoxy-14-methyl-5-oxa-12-azahexacyclo[8.7.2.1²,⁶.0¹,¹¹.0³,⁹.0¹⁴,¹⁸]icosan-4-one
(1s,3s,9r,10r,11r,14s,15r,16r)-10-ethyl-14-methyl-3-[(2s,4r)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
(1r,2s,3r,5r,7s,10r,11s,13s,14s,16s,17s,18s,19r)-4-ethyl-16-methoxy-10-methyl-6-oxa-4-azaheptacyclo[15.2.1.0²,⁷.0²,¹¹.0³,¹³.0⁵,¹⁰.0¹⁴,¹⁹]icosane-14,18-diol
(1r,2r,4s,5r,7r,8r,9r,10r,11r,13s,16s,17r)-11-ethyl-4,7,16-trihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-11-ium-11-olate
(1r,14s,16r,18r)-4,5,6,18-tetramethoxy-15-oxa-11-azapentacyclo[9.8.0.0¹,¹⁴.0²,⁷.0¹⁴,¹⁶]nonadeca-2(7),3,5-triene
C21H29NO5 (375.20456240000004)
3-[(2r,3r,8r,11s,12r,15s,16r)-15-hydroxy-12-(hydroxymethyl)-16-methyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-3-yl]propanoic acid
(2r,4ar,7s,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl (hydroxycarbamoyl)formate
4,5,6,18-tetramethoxy-15-oxa-11-azapentacyclo[9.8.0.0¹,¹⁴.0²,⁷.0¹⁴,¹⁶]nonadeca-2(7),3,5-triene
C21H29NO5 (375.20456240000004)
(1r,3r,9r,10r,11s,14s,15s,16r)-10-ethyl-14-methyl-3-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
15,18-dihydroxy-13-(2-hydroxyethyl)-11-methyl-19-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-one
(2s)-n-(5-carbamimidamido-1-oxopentan-2-yl)-2-[(1-hydroxy-2-methylpropylidene)amino]-3-phenylpropanimidic acid
(1s,2s,5r,8r,9r,10s,11r,13r,14s,15r,16r)-7-ethyl-2,11,14-trihydroxy-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate
(1r,3s,9r,10r,11r,14s,15r,16r)-10-ethyl-14-methyl-3-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
5-hydroxy-4-{hydroxy[6-(hydroxymethyl)-1-methyl-2-(prop-1-en-1-yl)-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methylidene}-2-(hydroxymethyl)-2h-pyrrol-3-one
C21H29NO5 (375.20456240000004)
(1r,2r,4s,5r,7r,8r,9r,10r,13s,16s,17r)-11-ethyl-4,7,16-trihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-11-ium-11-olate
hexahydro-1h-pyrrolizin-1-ylmethyl 2-hydroxy-2-methyl-3-[(2-phenylacetyl)oxy]butanoate
C21H29NO5 (375.20456240000004)
3-[(dimethylamino)methyl]-6,14-dimethyl-2-oxo-3h,3ah,4h,5h,8h,9h,12h,13h,15ah-cyclotetradeca[b]furan-10-carboxylic acid
11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,14,16-tetrol
(3s,3ar,6r,6ar,11s,13as)-1,6,11-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,6h,6ah,7h,10h,11h,12h-cyclonona[d]isoindol-13-one
(2s)-4-{[(1s,2r,4as,6r,8ar)-6-(hydroxymethyl)-1-methyl-2-(prop-1-en-1-yl)-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-(hydroxymethyl)-2h-pyrrol-3-one
C21H29NO5 (375.20456240000004)
(1s,2r,4r,5r,7r,8s,9r,10r,13s,16s,17r)-11-ethyl-4,7,16-trihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-11-ium-11-olate
(3r,3as,15ar)-3-[(dimethylamino)methyl]-6,14-dimethyl-2-oxo-3h,3ah,4h,5h,6h,9h,12h,13h,15ah-cyclotetradeca[b]furan-10-carboxylic acid
7-ethyl-2,11,14-trihydroxy-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate
4-ethyl-16-methoxy-10-methyl-6-oxa-4-azaheptacyclo[15.2.1.0²,⁷.0²,¹¹.0³,¹³.0⁵,¹⁰.0¹⁴,¹⁹]icosane-14,18-diol
(1s,3r,9s,10s,11r,14r,15r,16s)-10-ethyl-14-methyl-3-[(2r,4r)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
10-ethyl-14-methyl-3-(4-methyl-5-oxooxolan-2-yl)-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
(1s,2s,5r,7s,10s,11r,13r,14s,15r,16r)-7-ethyl-2,11,14-trihydroxy-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecan-7-ium-7-olate
7-(6-hydroxy-2,3,4,5-tetrahydropyridin-2-yl)-9-(hydroxymethyl)-octahydro-1h-quinolizin-2-yl 1h-pyrrole-2-carboxylate
C20H29N3O4 (375.21579540000005)
11-hydroxy-2,2,5-trimethyl-12-(3-methylbut-2-en-1-yl)-1-oxa-5-azatetraphen-10-one
C24H25NO3 (375.18343400000003)
7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl (hydroxycarbamoyl)formate
(1s,16s,17r)-4,5,6,17-tetramethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-16-ol
C21H29NO5 (375.20456240000004)
1-({15-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-trien-18-yl}oxy)butan-2-ol
C21H29NO5 (375.20456240000004)
(1r,3s,9r,10r,11s,14s,15s,16s)-10-ethyl-14-methyl-3-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadecan-13-one
11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-3,4,7,16-tetrol
(3r)-10-methoxy-3-methyl-3-(4-methylpent-3-en-1-yl)-11h-pyrano[3,2-a]carbazole-8-carbaldehyde
C24H25NO3 (375.18343400000003)
4,5,6,17-tetramethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-16-ol
C21H29NO5 (375.20456240000004)